12 February 2018
Source: Macular Society
Researchers in the south of England will become the first in the UK to trial a new drug that could prevent sight loss caused by Stargardt disease, a currently untreatable condition.
Stargardt disease, also known as Stargardt macular dystrophy, affects the area of the retina called the macula and causes a reduction in central vision.
It is the most common form of juvenile macular degeneration and affects around one in 10,000 children who suffer a gradual decline in vision which leads to blindness in adulthood.
Professor Andrew Lotery, from University Hospital Southampton NHS Foundation Trust, is to lead the UK’s team in a £5 million study of the drug remofuscin with colleagues in the Netherlands, Italy, Germany and Norway.
Speaking about the new trial, Professor Lotery said: “There is no approved treatment available for Stargardt’s, so we are very excited about the opportunity to test remofuscin and offer these patients the hope that we may be able to stop the progression of the condition.”
Full story on the Macular Society Website